Form 4: Neuraxis CEO Carrico Granted 94,173 RSUs

Neuraxis, Inc. CEO Brian Allen Carrico received a grant of 94,173 restricted stock units as part of his compensation package.

Summary

• Brian Allen Carrico, Chief Executive Officer and Director of Neuraxis, INC (NRXS), was granted 94,173 Restricted Stock Units (RSUs).
• The RSUs were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended.
• The grant date for these RSUs was January 22, 2026.
• Each RSU has a derivative security price of $4.63.
• The RSUs will vest in three equal annual installments over a three-year period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, primarily due to the alignment of executive incentives with shareholder interests, which is a standard and generally beneficial corporate governance practice. It is a routine compensation event rather than a significant operational or financial development.

Positives

• The grant of Restricted Stock Units (RSUs) to the CEO aligns management's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This compensation structure is a standard practice in corporate governance, designed to incentivize executive performance and retention.

Negatives

• The future conversion of RSUs into common stock will result in dilution for existing shareholders, increasing the total number of outstanding shares.
• Upon vesting, the CEO may sell some or all of the shares, which could potentially create selling pressure on the stock.

Risks

• Future dilution of existing shareholders when the 94,173 RSUs vest and convert into common stock.
• Potential for increased selling pressure on Neuraxis, INC's stock if the CEO sells vested shares in the open market.
• The value of the compensation is subject to the future performance and volatility of Neuraxis, INC's stock price.

Future Outlook

The RSUs are scheduled to vest in three equal annual installments over a three-year period, indicating a long-term incentive structure for the CEO.

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units (RSUs) is a prevalent form of executive compensation across various industries, particularly in biotechnology and healthcare, to attract, retain, and incentivize key leadership. This practice aligns executive interests with long-term shareholder value creation, a common strategy seen in companies like Moderna (MRNA) or BioNTech (BNTX) for their top executives.

Comparison to Industry Standards

• The grant of RSUs to a CEO is a standard component of executive compensation packages, comparable to practices at other publicly traded companies in the biotechnology and medical device sectors.
• The three-year vesting schedule is typical for long-term incentive plans, similar to those observed at companies such as Medtronic (MDT) or Boston Scientific (BSX) for their executive equity awards, aiming to promote sustained performance and retention.

Stakeholder Impact

• Shareholders: Potential for future dilution upon RSU vesting and conversion to common stock, but also increased alignment of CEO's interests with long-term stock performance.
• Employees: The RSU grant is part of an incentive plan, which may signal a commitment to performance-based compensation across the organization, potentially impacting employee morale and retention.

Next Steps

• The RSUs will vest in three equal annual installments over a three-year period, starting from the grant date of January 22, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant of Restricted Stock Units (RSUs) to the CEO. While it aligns management's interests with shareholders, it does not present new material information that would fundamentally alter the company's financial outlook or operational performance. Therefore, a 'hold' recommendation is appropriate as it's a standard corporate event that doesn't warrant a change in investment thesis based solely on this filing.

Keywords

Neuraxis, NRXS, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Brian Carrico, Corporate Governance